Registration No.

================================================================================

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

---------------

FORM S-8
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933

---------------

PDI, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware 22-2919486
(State or Other Jurisdiction of (I.R.S. Employer Identification No.)
Incorporation or Organization)

Saddle River Executive Centre
1 Route 17 South
Saddle River, New Jersey 07458
(201) 258-8450
(Address, Including Zip Code, and Telephone Number
of Registrant's Principal Executive Offices)

---------------

2004 Stock Award and Incentive Plan
(Full Title of the Plan)

---------------

Beth R. Jacobson
Executive Vice President, General Counsel and Corporate Secretary
PDI, Inc.
Saddle River Executive Centre
1 Route 17 South
Saddle River, New Jersey 07458
(201) 258-8450
(Name, Address and Telephone Number,
Including Area Code, of Agent for Service)

---------------

CALCULATION OF REGISTRATION FEE

- -------------------------------------------------------------------------------------------------------------
Proposed Maximum Proposed Maximum Amount of
Title of Securities To Be Amount To Be Offering Price Aggregate Offering Registration
Registered Registered (1) Per Share (2) Price (3) Fee
- -------------------------------------------------------------------------------------------------------------

Common Stock, par value $.01 per 1,329,132 $19.98 $17,860,442 $2,102.17
share shares

(1) Pursuant to Instruction E of Form S-8 and the telephonic interpretation of
the Securities and Exchange Commission (the "SEC") set forth at pages
123-124 of the Division of Corporation Finance's Manual of Publicly
Available Telephone Interpretations, dated July 1997 (see G. Securities Act
Forms, No. 89 ("Interpretation 89")), 29,211 shares out of the 1,329,132
shares registered hereby are being carried forward from a registration
statement filed on August 12, 1998 (File No. 333-61231) (the "1998 Form
S-8"), in connection with the 1998 Stock Option Plan and 406,005 shares out
of the 1,329,132 shares registered hereby are being carried forward from a
registration statement filed on May 9, 2001 (File No. 333-60512) (the "2000
Form S-8"), in connection with the PDI Inc. 2000 Omnibus Incentive
Compensation Plan, each a predecessor plan to the PDI Inc. 2004 Stock Award
and Incentive Plan described herein. A total registration fee of $4,057.60
has been paid with respect to the 1998 Form S-8 and a total registration
fee of $27,666 has been paid with respect to the 2000 Form S-8. Pursuant to
Instruction E of Form S-8 and Interpretation 89, no additional registration
fee is due with respect to the 435,216 shares registered hereby that are
being carried forward.

This registration statement, pursuant to Rule 416 under the Securities Act
of 1933, as amended (the "Act"), covers any additional shares of common
stock, par value $.01 per share ("Common Stock"), of PDI, Inc. (the
"Registrant"), which become issuable under the 2004 Stock Award and
Incentive Plan by reason of any stock dividend, stock split,
recapitalization, exchange of shares or other similar transaction effected
without receipt of consideration which results in an increase in the number
of shares of Common Stock outstanding.

(2) The proposed maximum offering price per share was estimated solely for the
purpose of calculating the registration fee in accordance with Rule 457(h)
under the Act and is based on the average of the high and low prices for
the Common Stock on the NASDAQ National Market System on March 9, 2005 of
$19.98 per share.

(3) The proposed maximum aggregate offering price is calculated based on the
893,916 shares of Common Stock not being carried forward from the 1998 Form
S-8 or the 2000 Form S-8.

================================================================================

EXPLANATORY NOTE

The Registrant has prepared this registration statement in accordance
with the requirements of Form S-8 under the Act, to register shares of its
Common Stock pursuant to its 2004 Stock Award and Incentive Plan. Under cover of
this Form S-8 is a reoffer prospectus that the Registrant prepared in accordance
with Part I of Form S-3 under the Act. The reoffer prospectus may be utilized
for reofferings and resales of up to 1,329,132 shares of common stock acquired
by the prospective selling stockholders under the 2004 Stock Award and Incentive
Plan. (In the event of a future anti-dilution adjustment relating to the number
of shares issuable upon exercise of the options, the number of shares set forth
in the reoffer prospectus will be appropriately adjusted.) The reoffer
prospectus does not contain all the information set forth in the registration
statement, certain items of which are contained in schedules and exhibits to the
registration statement as permitted by the rules and regulations of the SEC.
Statements contained in the reoffer prospectus as to the contents of any
agreement, instrument or other document are not necessarily complete. With
respect to each such agreement, instrument or other document filed as an exhibit
to the registration statement, reference is made to the exhibit for a more
complete description of the matter involved, and each such statement shall be
deemed qualified in its entirety by such reference.

REOFFER PROSPECTUS

1,329,132 Shares

PDI, Inc.

Common Stock

This reoffer prospectus relates to 1,329,132 shares of common stock,
par value $.01 per share, of PDI, Inc., or PDI, that may be offered for sale
from time to time by the selling stockholders named herein or in a supplement to
this reoffer prospectus. The selling stockholders may acquire the common stock
in connection with PDI's 2004 Stock Award and Incentive Plan (the "Stock Plan").
We will not receive any proceeds from the sale of shares of common stock by any
selling stockholder.

You should read this prospectus and any accompanying prospectus
supplement carefully before you make your investment decision. The prospectus
supplement will describe the means of distribution for any shares of common
stock sold by the selling stockholders. For general information about the
distribution of the common stock offered, please see "Plan of Distribution" in
this prospectus.

PDI's common stock is listed on the NASDAQ National Market System under
the trading symbol "PDII".

INVESTING IN THE COMMON STOCK INVOLVES RISKS. SEE "RISK FACTORS"
BEGINNING ON PAGE 1.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES
COMMISSION OR ANY OTHER REGULATORY BODY HAS APPROVED OR DISAPPROVED OF THESE
SECURITIES OR DETERMINED IF THIS PROSPECTUS OR THE ACCOMPANYING PROSPECTUS
SUPPLEMENT IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.

The date of this Reoffer Prospectus is March 14, 2005.

TABLE OF CONTENTS

THE COMPANY....................................................................1

RISK FACTORS...................................................................1

USE OF PROCEEDS...............................................................10

SELLING STOCKHOLDERS..........................................................10

PLAN OF DISTRIBUTION..........................................................10

LEGAL MATTERS.................................................................11

EXPERTS.......................................................................11

AVAILABLE INFORMATION.........................................................11

DOCUMENTS INCORPORATED BY REFERENCE...........................................11

INDEMNIFICATION...............................................................12

You should rely only on the information contained or incorporated by
reference in this prospectus and any accompanying prospectus supplement. Neither
we nor the selling stockholders have authorized anyone to provide you with
additional or different information. If anyone provided you with additional or
different information, you should not rely on it. Neither we nor the selling
stockholders are making an offer to sell or soliciting an offer to buy these
securities in any jurisdiction where such offer, solicitation or sale is not
permitted. You should assume that the information contained in this prospectus
and any accompanying prospectus supplement is accurate only as of their
respective dates and that any information incorporated by reference is accurate
only as of the date of the document incorporated by reference. Our business,
financial condition, results of operations and prospects may have changed since
those dates.

Unless otherwise stated or the context otherwise requires, references
in this prospectus to "we," "us," and "our" refer to PDI, Inc. and its
subsidiaries as a consolidated entity, while references to "PDI" refer only to
PDI, Inc. on a non-consolidated basis.

THE COMPANY

We are a diversified sales and marketing services company serving the
biopharmaceutical and medical devices and diagnostics (MD&D) industries.

We create and execute sales and marketing programs intended to improve the
profitability of biopharmaceutical and MD&D products. We do this by working with
companies who recognize our ability to add value to their products and maximize
their sales performance. We have a variety of agreement types that we enter into
with our clients. In these agreements, we leverage our experience in sales,
medical education and marketing research to help our partners and clients meet
strategic and financial objectives.

We have assembled our commercial capabilities through organic growth,
acquisitions, and internal expansion. These capabilities can be applied on a
stand-alone or integrated basis. This flexibility enables us to provide a wide
range of marketing and promotional options that can benefit many different
products throughout the various stages of their life cycles.

It is important for us to form strong relationships with companies within
the biopharmaceutical and MD&D industries. Our focus is to achieve operational
excellence that delivers the desired product sales results.

We are among the leaders in outsourced sales and marketing services in the
U.S. We have designed and implemented programs for many of the major
pharmaceutical companies serving the U.S. market. Our clients include
AstraZeneca PLC (AstraZeneca), GlaxoSmithKline PLC (GSK), Novartis
Pharmaceutical Corporation (Novartis), Pfizer Inc. (Pfizer) and Sanofi-Aventis
AG (Sanofi-Aventis), as well as many small and specialty pharmaceutical
companies. Our relationships are built on consistent performance and program
results.

Our clients engage us on a contractual basis to design and
implement promotional programs for both prescription and over-the-counter
products. The programs are designed to increase product sales and are tailored
to meet the specific needs of the product and the client. These services are
provided predominantly on a fee for service basis. Occasionally, there is an
opportunity for us to earn incentives if we meet or exceed predetermined
performance targets. Contracts may also be terminated for cause, or we may incur
specific penalties if we fail to meet stated performance benchmarks.

RISK FACTORS

Prospective investors should carefully review the following factors
together with the other information contained in, or incorporated by reference
into, this prospectus and any accompanying prospectus supplement prior to making
an investment decision.

In addition to the other information provided in our reports, you
should carefully consider the following factors in evaluating our business,
operations and financial condition. Additional risks and uncertainties not
presently known to us, that we currently deem immaterial or that are similar to
those faced by other companies in our industry or business in general, such as
competitive conditions, may also impair our business operations. The

occurrence of any of the following risks could have a material adverse effect on
our business, financial condition and results of operations. You should also
refer to the other information included in this prospectus.

OUR SERVICE BUSINESSES DEPEND ON EXPENDITURES BY COMPANIES IN THE LIFE SCIENCES
INDUSTRIES.

Our service revenues depend on promotional, marketing and sales
expenditures by companies in the life sciences industries, including the
pharmaceutical, MD&D and biotechnology industries. Promotional, marketing and
sales expenditures by pharmaceutical manufacturers have in the past been, and
could in the future be, negatively impacted by, among other things, governmental
reform or private market initiatives intended to reduce the cost of
pharmaceutical products or by governmental, medical association or
pharmaceutical industry initiatives designed to regulate the manner in which
pharmaceutical manufacturers promote their products. Furthermore, the trend in
the life sciences industries toward consolidation may result in a reduction in
overall sales and marketing expenditures and, potentially, a reduction in the
use of contract sales and marketing services providers.

CHANGES IN OUTSOURCING TRENDS IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES
COULD MATERIALLY ADVERSELY AFFECT OUR BUSINESS, FINANCIAL CONDITION, RESULTS OF
OPERATIONS AND GROWTH RATE.

Our business and growth depend in large part on demand from the
pharmaceutical and life sciences industries for outsourced marketing and sales
services. The practice of many companies in these industries has been to hire
outside organizations like us to conduct large sales and marketing projects.
However, companies may elect to perform these services internally for a variety
of reasons, including the rate of new product development and U.S. Food and Drug
Administration (FDA) approval of those products, number of sales representatives
employed internally in relation to demand for or the need to promote new and
existing products, and competition from other suppliers. If these industries
reduce their tendency to outsource these projects, our business, financial
condition, results of operations and growth rate could be materially adversely
affected.

MOST OF OUR SERVICE REVENUE IS DERIVED FROM A LIMITED NUMBER OF CLIENTS, THE
LOSS OF ANY ONE OF WHICH COULD ADVERSELY AFFECT OUR BUSINESS.

Our revenue and profitability depend to a great extent on our
relationships with a limited number of large pharmaceutical companies. In 2004,
we had two major clients that accounted for approximately 42.0% and 21.0%,
respectively, or a total of approximately 63.0%, of our service revenue. In
2003, our two major clients accounted for a total of approximately 66.5% of our
service revenue. We are likely to continue to experience a high degree of client
concentration, particularly if there is further consolidation within the
pharmaceutical industry. The loss or a significant reduction of business from
any of our major clients could have a material adverse effect on our business,
financial condition and results of operations. For example, in December 2004, we
announced a reduction in the aggregate number of representatives that we
deployed for AstraZeneca. This reduction is expected to decrease revenue
generated from AstraZeneca in 2005 by approximately $60.0 million as compared to
revenues generated in 2004.

PRODUCT LIABILITY CLAIMS COULD HARM OUR BUSINESS.

We could face substantial product liability claims in the event any of the
pharmaceutical and medical device products we market now or in the future are
alleged to cause negative reactions or adverse side effects or in the event any
of these products causes injury, is alleged to be unsuitable for its intended
purpose or is alleged to be otherwise defective. For example, we have been named
in numerous lawsuits as a result of our detailing of Baycol(R) on behalf of
Bayer Corporation (Bayer). Product liability claims, regardless of their merits,
could be costly and divert management's attention, or adversely affect our
reputation and the demand for our products. Although we currently have product
liability insurance in the aggregate amount of $10.0 million, we cannot assure
you that our insurance will be sufficient to cover fully all potential claims.
Also, adequate insurance coverage might not be available in the future at
acceptable costs, if at all.

IF WE DO NOT MEET PERFORMANCE GOALS SET IN OUR INCENTIVE-BASED AND REVENUE
SHARING ARRANGEMENTS, OUR PROFITS COULD SUFFER.

We sometimes enter into incentive-based and revenue sharing arrangements
with pharmaceutical companies. Under incentive-based arrangements, we are
typically paid a fixed fee and, in addition, have an opportunity to increase our
earnings based on the market performance of the products being detailed in
relation to targeted sales volumes, sales force performance metrics or a
combination thereof. Additionally, certain of our service contracts may contain
penalty provisions pursuant to which our fees may be significantly reduced if we
do not meet certain performance metrics, for example number and timing of sales
calls, physician reach, territory vacancies and/or sales representative
turnover. Under revenue sharing arrangements, our compensation is based on the
market performance of the products being detailed, usually expressed as a
percentage of product sales. These types of arrangements transfer some market
risk from our clients to us. In addition, these arrangements can result in
variability in revenue and earnings due to seasonality of product usage, changes
in market share, new product introductions, overall promotional efforts and
other market related factors. As an example, in October 2001, we entered into an
agreement with Eli Lilly to copromote Evista(R) in the U.S. under which we were
to receive payments once product net sales exceeded a pre-determined baseline.
The net sales of Evista were insufficient for us to achieve our revenue and
profit goals and as a result we incurred an operating loss for 2002 of $35.1
million on this contract, consisting of $28.9 million from operating activities
and $6.2 million in unused sales force capacity. This contract was terminated
effective December 31, 2002.

OUR SERVICE CONTRACTS ARE GENERALLY SHORT-TERM AGREEMENTS AND ARE CANCELABLE AT
ANY TIME, WHICH MAY RESULT IN LOST REVENUE AND ADDITIONAL COSTS AND EXPENSES.

Our service contracts are generally for a term of one to three years
(certain of our operating entities have contracts of shorter duration) and many
may be terminated by the client at any time for any reason. Additionally,
certain of our clients have the ability to significantly reduce the number of
representatives we deploy on their behalf. For example, as discussed above, as a
result of the reduction in the number of representatives we deployed for
AstraZeneca and the early termination of our fee for service contract
arrangement with Novartis, we expect to generate approximately $60.0 million
less revenue from our AstraZeneca relationship in 2005 than we realized in 2004,
and $28.9 million of originally anticipated revenue associated with the Novartis
contract in 2004 was not realized. The termination or significant reduction of a
contract by one of our major clients not only results in lost revenue, but also
may cause us to incur additional costs and expenses. All of our sales
representatives are employees rather than independent contractors. Accordingly,
when a contract is significantly reduced or terminated, unless we can
immediately transfer the related sales force to a new program, we must either
continue to compensate those employees, without realizing any related revenue,
or terminate their employment. If we terminate their employment, we may incur
significant expenses relating to their termination. The loss, termination or
significant reduction of a large contract or the loss of multiple contracts
could have a material adverse effect on our business, financial condition and
results of operations.

WE MAY MAKE ACQUISITIONS IN THE FUTURE WHICH MAY LEAD TO DISRUPTIONS TO OUR
ONGOING BUSINESS.

Historically, we have made a number of acquisitions and will continue to
review new acquisition opportunities. If we are unable to successfully integrate
an acquired company, the acquisition could lead to disruptions to our business.
The success of an acquisition will depend upon, among other things, our ability
to:

o assimilate the operations and services or products of the acquired company;

o integrate new personnel due to the acquisition;

o retain and motivate key employees;

o retain customers; and

o minimize the diversion of management's attention from other business
concerns.

In the event that the operations of an acquired business do not meet our
performance expectations, we may have to restructure the acquired business or
write-off the value of some or all of the assets of the acquired business,
including goodwill and other intangible assets identified at time of
acquisition.

WE AND TWO OF OUR OFFICERS ARE DEFENDANTS IN A CLASS ACTION SHAREHOLDER LAWSUIT
WHICH COULD DIVERT OUR TIME AND ATTENTION FROM MORE PRODUCTIVE ACTIVITIES.

Beginning on January 24, 2002, several purported class action complaints
were filed in the U.S. District Court for the District of New Jersey, against us
and certain of our officers on behalf of persons who purchased our common stock
during the period between May 22, 2001 and August 12, 2002. On May 23, 2002, the
court consolidated these suits into a single class action lawsuit. We believe
that meritorious defenses exist to the allegations asserted in this lawsuit and
we intend to vigorously defend this action. Although we currently maintain
director and officer liability insurance coverage, there is no assurance that we
will continue to maintain such coverage or that any such coverage will be
adequate to offset potential damages.

OUR FAILURE, OR THAT OF OUR CLIENTS, TO COMPLY WITH APPLICABLE HEALTHCARE
REGULATIONS COULD LIMIT, PROHIBIT OR OTHERWISE ADVERSELY IMPACT OUR BUSINESS
ACTIVITIES.

Various laws, regulations and guidelines established by government,
industry and professional bodies affect, among other matters, the provision of,
licensing, labeling, marketing, promotion, sale and distribution of healthcare
services and products, including pharmaceutical and MD&D products. In
particular, the healthcare industry is governed by various federal and state
laws pertaining to healthcare fraud and abuse, including prohibitions on the
payment or acceptance of kickbacks or other remuneration in return for the
purchase or lease of products that are paid for by Medicare or Medicaid.
Sanctions for violating these laws include civil and criminal fines and
penalties and possible exclusion from Medicare, Medicaid and other federal or
state healthcare programs. Although we believe our current business arrangements
do not violate these federal and state fraud and abuse laws, we cannot be
certain that our business practices will not be challenged under these laws in
the future or that a challenge would not have a material adverse effect on our
business, financial condition and results of operations. Our failure, or the
failure of our clients, to comply with these laws, regulations and guidelines,
or any change in these laws, regulations and guidelines may, among other things,
limit or prohibit our business activities or those of our clients, subject us or
our clients to adverse publicity, increase the cost of regulatory compliance and
insurance coverage or subject us or our clients to monetary fines or other
penalties.

OUR INDUSTRY IS HIGHLY COMPETITIVE AND OUR FAILURE TO ADDRESS COMPETITIVE
DEVELOPMENTS PROMPTLY WILL LIMIT OUR ABILITY TO RETAIN AND INCREASE OUR MARKET
SHARE.

Our primary competitors for sales and marketing services include in-house
sales and marketing departments of pharmaceutical companies, other contract
sales organizations (CSOs) and medical education and marketing research
providers. There are relatively few barriers to entry in the businesses in which
we compete and, as the industry continues to evolve, new competitors are likely
to emerge. Many of our current and potential competitors are larger than we are
and have substantially greater capital, personnel and other resources than we
have. Increased competition may lead to competitive practices that could have a
material adverse effect on our market share, our ability to source new business
opportunities, our business, financial condition and results of operations.

OUR STOCK PRICE IS VOLATILE AND COULD BE FURTHER AFFECTED BY EVENTS NOT WITHIN
OUR CONTROL. IN 2004, OUR STOCK TRADED AT A LOW OF $18.94 AND A HIGH OF $33.23.
IN 2003, OUR STOCK TRADED AT A LOW OF $6.86 AND A HIGH OF $31.71.

The market for our common stock is volatile. The trading price of our
common stock has been and will continue to be subject to:

o volatility in the trading markets generally;

o significant fluctuations in our quarterly operating results;

o announcements regarding our business or the business of our competitors;

o industry developments;

o regulatory developments;

o changes in revenue mix;

o changes in revenue and revenue growth rates for us and for our industry as
a whole; and

o statements or changes in opinions, ratings or earnings estimates made by
brokerage firms or industry analysts relating to the markets in which we
operate or expect to operate.

OUR QUARTERLY REVENUES AND OPERATING RESULTS MAY VARY, WHICH MAY CAUSE THE PRICE
OF OUR COMMON STOCK TO FLUCTUATE.

Our quarterly operating results may vary as a result of a number of
factors, including:

o the commencement, delay, cancellation or completion of programs;

o regulatory developments;

o uncertainty related to compensation based on achieving performance
benchmarks;

o the mix of services provided;

o the mix of programs -- i.e., contract sales, medical education, marketing
research;

o the timing and amount of expenses for implementing new programs and
services and acquiring license rights for products;

o the accuracy of estimates of resources required for ongoing programs;

o the timing and integration of acquisitions;

o changes in regulations related to pharmaceutical companies; and

o general economic conditions.

In addition, in the case of revenue related to service contracts, we
recognize revenue as services are performed, while program costs, other than
training costs, are expensed as incurred. As a result, during the first two to
three months of a new contract, we may incur substantial expenses associated
with implementing that new program without recognizing any revenue under that
contract. This could have a material adverse impact on our operating results and
the price of our common stock for the quarters in which these expenses are
incurred. For these and other reasons, we believe that quarterly comparisons of
our financial results are not necessarily meaningful and should not be relied
upon as an indication of future performance. Fluctuations in quarterly results
could materially adversely affect the market price of our common stock in a
manner unrelated to our long-term operating performance.

WE MAY REQUIRE ADDITIONAL FUNDS IN ORDER TO IMPLEMENT OUR EVOLVING BUSINESS
MODEL.

We may require additional funds in order to:

o pursue other business opportunities or meet future operating requirements;

o develop incremental marketing and sales capabilities;

o acquire other services businesses;

o license or acquire additional pharmaceutical or medical device products or
technologies; and/or

o pursue regulatory approvals.

We may seek additional funding through public or private equity or debt
financing or other arrangements with collaborative partners. If we raise
additional funds by issuing equity securities, further dilution to existing
stockholders may result. In addition, as a condition to providing us with
additional funds, future investors may demand, and may be granted, rights
superior to those of existing stockholders. We cannot be sure, however, that
additional financing will be available from any of these sources or, if
available, will be available on acceptable or affordable terms. If adequate
additional funds are not available, we may be required to delay, reduce the
scope of, or eliminate one or more of our growth strategies.

IF WE ARE UNABLE TO ATTRACT KEY EMPLOYEES AND CONSULTANTS, WE MAY BE UNABLE TO
SUPPORT THE GROWTH OF OUR BUSINESS.

Successful execution of our business strategy depends, in large part, on
our ability to attract and retain qualified management, marketing and other
personnel with the skills and qualifications necessary to fully execute our
programs and strategy. Competition for personnel among companies in the
pharmaceutical industry is intense and we cannot assure you that we will be able
to continue to attract or retain the personnel necessary to support the growth
of our business.

OUR BUSINESS MAY SUFFER IF WE FAIL TO ATTRACT AND RETAIN QUALIFIED SALES
REPRESENTATIVES.

The success and growth of our business depends on our ability to attract
and retain qualified pharmaceutical sales representatives. There is intense
competition for pharmaceutical sales representatives from CSOs and
pharmaceutical companies. On occasion, our clients have hired the sales
representatives that we trained to detail their products. We cannot be certain
that we can continue to attract and retain qualified personnel. If we cannot
attract and retain qualified sales personnel, we will not be able to expand our
teams business and our ability to perform under our existing contracts will be
impaired.

OUR BUSINESS WILL SUFFER IF WE LOSE CERTAIN KEY MANAGEMENT PERSONNEL.

The success of our business also depends on our ability to attract and
retain qualified senior management, and financial and administrative personnel
who are in high demand and who often have multiple employment options.
Currently, we depend on a number of our senior executives, including Charles T.
Saldarini, our chief executive officer and vice chairman of our board of
directors, Steven K. Budd, our president, global sales and marketing services,
and Bernard C. Boyle, our chief financial officer. The loss of the services of
any one or more of these executives could have a material adverse effect on our
business, financial condition and results of operations. Except for a $5 million
key-man life insurance policy on the life of Mr. Saldarini and a $3 million
policy on the life of Mr. Budd and life insurance policies on two other
executives, we do not maintain and do not contemplate obtaining insurance
policies on any of our employees.

OUR CONTROLLING STOCKHOLDER CONTINUES TO HAVE EFFECTIVE CONTROL OF US, WHICH
COULD DELAY OR PREVENT A CHANGE IN CORPORATE CONTROL THAT MAY OTHERWISE BE
BENEFICIAL TO OUR STOCKHOLDERS.

John P. Dugan, our chairman, beneficially owns approximately 33.0% of our
outstanding common stock. As a result, Mr. Dugan will be able to exercise
substantial control over the election of all of our directors, and to determine
the outcome of most corporate actions requiring stockholder approval, including
a merger with or into another company, the sale of all or substantially all of
our assets and amendments to our certificate of incorporation.

WE HAVE ANTI-TAKEOVER DEFENSES THAT COULD DELAY OR PREVENT AN ACQUISITION AND
COULD ADVERSELY AFFECT THE PRICE OF OUR COMMON STOCK.

Our certificate of incorporation and bylaws include provisions, such as
providing for three classes of directors, which are intended to enhance the
likelihood of continuity and stability in the composition of our board of
directors. These provisions may make it more difficult to remove our directors
and management and may adversely affect the price of our common stock. In
addition, our certificate of incorporation authorizes the issuance of "blank
check" preferred stock. This provision could have the effect of delaying,
deterring or preventing a future takeover or a change in control, unless the
takeover or change in control is approved by our board of directors, even though
the transaction might offer our stockholders an opportunity to sell their shares
at a price above the current market price.

RISK FACTORS MORE CLOSELY ASSOCIATED WITH THE PPG SEGMENT OF OUR BUSINESS:

WE MAY CONTINUE TO REVIEW OPPORTUNITIES FOR THE PPG SEGMENT OF OUR BUSINESS,
WHICH MAY INCLUDE COPROMOTION AND EXCLUSIVE DISTRIBUTION ARRANGEMENTS, AS WELL
AS LICENSING AND BRAND OWNERSHIP OF PRODUCTS. WE CANNOT ASSURE YOU THAT WE CAN
SUCCESSFULLY DEVELOP THIS BUSINESS.

Notwithstanding the fact that we had only approximately $2.9 million in
revenue from the PPG segment of our business in 2004, we may continue to review
opportunities which may include copromotion, distribution arrangements, as well
as licensing and brand ownership of products. These types of arrangements can
significantly increase our operating expenditures in the short-term. Typically,
these agreements require significant "upfront" payments, minimum purchase
requirements, minimum royalty payments, payments to third parties for
production, inventory maintenance and control, distribution services and
accounts receivable administration, as well as sales and marketing expenditures.
In addition, particularly where we license or acquire products before they are
approved for commercial use, we may be required to incur significant expense to
gain the required regulatory approvals. As a

result, our working capital balance and cash flow position could be materially
and adversely affected until the products in question become commercially
viable, if ever. The risks that we face in developing the PPG segment of our
business may increase in proportion with:

o the number and types of products covered by these types of agreements;

o the applicable stage of the drug regulatory process of the products at the
time we enter into these agreements; and

o our control over the manufacturing, distribution and marketing processes.

In December 2002, we acquired from Cellegy Pharmaceuticals, Inc. (Cellegy)
the exclusive right to market and sell Fortigel(TM), a transdermal testosterone
gel for the treatment of male hypogonadism in the U.S., Puerto Rico, Mexico and
Canada. While we have entered into copromotion and exclusive distribution
arrangements in the past, the license agreement we entered into with Cellegy on
December 31, 2002 regarding Fortigel (the Cellegy License Agreement) was our
first licensing arrangement. We paid an initial $15.0 million license fee and
another $10.0 million incremental license fee milestone payment is due after the
product has all FDA approvals (if such approvals are obtained) required to
promote, sell and distribute the product in the U.S. If the drug is approved, in
addition to paying Cellegy a royalty based on net sales, all of the costs
associated with manufacturing the drug, distributing it, as well as sales and
marketing expenditures would be our obligation. If additional testing is
required after the drug is approved for sale in the U.S., the costs associated
with those tests are our obligation as well. Furthermore, if we want to sell the
drug in Mexico and Canada, we must fund the regulatory process in those
countries.

In July 2003, Cellegy received a letter from the FDA rejecting its New
Drug Application (NDA) for Fortigel. In December 2003, we filed a lawsuit
against Cellegy as we believed they fraudulently induced us to enter the Cellegy
License Agreement and for breaching certain obligations under the Cellegy
License Agreement. (SEE the Risk Factor describing the Cellegy litigation in
this section, below.) Cellegy has told us that, in the first quarter of 2005, it
received FDA approval for the protocol parameters for a new Phase 3 study
proposed by Cellegy to the FDA. We do not know when, or even whether, Cellegy
will conduct such a new Phase 3 study, and cannot predict with any certainty
whether the FDA will ultimately approve Fortigel for sale in the U.S.

WE ARE INVOLVED IN LAWSUITS WITH CELLEGY CONCERNING THE CELLEGY LICENSE
AGREEMENT.

On December 12, 2003, we filed a complaint against Cellegy in the U.S.
District Court for the Southern District of New York. The complaint alleges that
Cellegy fraudulently induced us to enter into the Cellegy License Agreement on
December 31, 2002. The complaint also alleges claims for misrepresentation and
breach of contract related to the Cellegy License Agreement. In the complaint,
we seek, among other things, rescission of the Cellegy License Agreement and
return of the $15.0 million we paid Cellegy. After we filed this lawsuit, also
on December 12, 2003, Cellegy filed a complaint against us in the U.S. District
Court for the Northern District of California. Cellegy's complaint seeks a
declaration that Cellegy did not fraudulently induce us to enter the Cellegy
License Agreement and that Cellegy has not breached its obligations under the
Cellegy License Agreement. We are unable to predict the ultimate outcome of
these lawsuits. The trial is scheduled to commence during the second quarter of
2005. Material legal expense has been and is expected to continue to be incurred
in connection with this lawsuit; however, at this time we are not able to
estimate the magnitude of the expense.

WE RELY ON THIRD PARTIES TO MANUFACTURE ALL OF OUR PRODUCTS AND SUPPLY RAW
MATERIALS. OUR DEPENDENCE ON THESE THIRD PARTIES MAY RESULT IN UNFORESEEN DELAYS
OR OTHER PROBLEMS BEYOND OUR CONTROL, WHICH COULD HAVE A MATERIAL ADVERSE EFFECT
ON OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS AND OUR
REPUTATION.

We do not manufacture any products and expect to continue to depend on
third parties to provide us with sufficient quantities of products to meet
demand. As a result, we cannot assure you that we will always have a sufficient
supply of products on hand to satisfy demand or that the products we do have
will meet our specifications. This risk is more acute in those situations where
we have no control over the manufacturers. For example, the Cellegy License
Agreement obligates us to purchase all quantities of the product from PanGeo
Pharma Inc. (PanGeo), a third-party manufacturer with which we have no
contractual relationship and to which Cellegy has granted exclusive
manufacturing rights. If there are any problems with this contract manufacturer,
the supply of product could be temporarily halted until either PanGeo is able to
get their facilities back on-line or we are able to source another supplier for
the product. This manufacturing shutdown could have a material impact on the
future

demand for the product and thus could have a material adverse effect on our
business, financial condition and results of operations. Even if third-party
manufacturers comply with the terms of their supply arrangements, we cannot be
certain that supply interruptions will not occur or that our inventory will
always be adequate. Numerous factors could cause interruptions in the supply of
our finished products, including shortages in raw materials, strikes and
transportation difficulties. Any disruption in the supply of raw materials or an
increase in the cost of raw materials to our supplier could have a significant
effect on its ability to supply us with products.

In addition, manufacturers of products requiring FDA approval are required
to comply with FDA mandated standards, referred to as good manufacturing
practices, relating not only to the manufacturing process but to record-keeping
and quality control activities as well. Furthermore, they must pass a
pre-approval inspection of manufacturing facilities by the FDA and foreign
authorities before obtaining marketing approval, and are subject to periodic
inspection by the FDA and corresponding foreign regulatory authorities under
reciprocal agreements with the FDA. These inspections may result in compliance
issues that could prevent or delay marketing approval or require significant
expenditures on corrective measures.

If for any reason we are unable to obtain or retain our relationships with
third-party manufacturers on commercially acceptable terms, or if we encounter
delays or difficulties with contract manufacturers in producing or packaging our
products, the distribution, marketing and subsequent sales of these products
would be adversely affected, and we may have to seek alternative sources of
supply. We cannot assure you that we will be able to maintain our existing
manufacturing relationships or enter into new ones on commercially acceptable
terms, if at all.

OUR LICENSE AGREEMENTS MAY REQUIRE US TO MAKE MINIMUM PAYMENTS TO THE LICENSOR,
REGARDLESS OF THE REVENUE DERIVED UNDER THE LICENSE, WHICH COULD FURTHER STRAIN
OUR WORKING CAPITAL AND CASH FLOW POSITION. IN ADDITION, THESE AGREEMENTS MAY BE
NONEXCLUSIVE OR MAY CONDITION EXCLUSIVITY ON MINIMUM SALES LEVELS.

Under the Cellegy License Agreement, we are required to make certain
minimum royalty payments to Cellegy once the product is approved by the FDA,
assuming such an approval occurs. If the Cellegy product fails to gain market
acceptance, we would still be required to make these minimum royalty payments.
This would likely have a material adverse effect on our business, financial
condition and results of operations. In addition, the Cellegy License Agreement
requires us to satisfy certain minimum net sales requirements. If we fail to
satisfy these minimum net sales requirements, under certain circumstances
Cellegy may, at its option, convert our exclusive license to a nonexclusive
license. This could mean that we would face increased competition from third
parties with respect to the marketing and sale of the product.

WE MAY BE UNABLE TO SECURE OR ENFORCE ADEQUATE INTELLECTUAL PROPERTY RIGHTS TO
PROTECT THE PRODUCTS OR TECHNOLOGIES WE ACQUIRE, LICENSE OR DEVELOP.

Our ability to successfully commercialize newly branded products or
technologies depends on our ability to secure and enforce intellectual property
rights, generally patents, and we may be unable to do so. To obtain patent
protection, we must be able to successfully persuade the U.S. Patent and
Trademark Office and its foreign counterparts to issue patents on a timely basis
and possibly in the face of third-party challenges. Even if we are granted a
patent, our rights may later be challenged or circumvented by third parties.
Likewise, a third-party may challenge our trademarks or, alternatively, use a
confusingly similar trademark. The issuance of a patent is not conclusive as to
its validity or enforceability and the patent life is limited. In addition, from
time to time, we might receive notices from third parties regarding patent
claims against us. These types of claims, with or without merit, could be
time-consuming to defend, result in costly litigation, divert management's
attention and resources, and cause us to incur significant expenses. As a result
of litigation over intellectual property rights, we may be required to stop
selling a product, obtain a license from the owner to sell the product in
question or use the relevant intellectual property, which we may not be able to
obtain on favorable terms, if at all, or modify a product to avoid using the
relevant intellectual property. A successful claim of infringement against us
could have a material adverse effect on our business, financial condition and
results of operations.

THE REGULATORY APPROVAL PROCESS IS EXPENSIVE, TIME CONSUMING AND UNCERTAIN AND
MAY PREVENT US FROM OBTAINING REQUIRED APPROVALS FOR THE COMMERCIALIZATION OF
DRUGS AND PRODUCTS THAT WE LICENSE OR ACQUIRE.

In those potential situations where we license or acquire ownership of
drugs or other medical or diagnostic equipment, the product in question may not
yet be approved for sale to the public, in which case we may have the obligation
to obtain the required regulatory approvals. The research, testing,
manufacturing and marketing of drugs and other medical and diagnostic devices is
heavily regulated in the U.S. and other countries. The regulatory clearance
process typically takes many years and is extremely expensive. Despite the time
and expense expended, regulatory clearance is never guaranteed. The FDA can
delay, limit or deny approval of a drug for many reasons, including:

o safety or efficacy;

o inconsistent or inconclusive data or test results;

o failure to demonstrate compliance with the FDA's good manufacturing
practices; or

o changes in the approval process or new regulations.

THE FDA CONTINUES TO REGULATE THE SALE AND MARKETING OF DRUGS AND MEDICAL AND
DIAGNOSTIC DEVICES EVEN AFTER THEY HAVE BEEN APPROVED FOR SALE TO THE PUBLIC.
COMPLYING WITH THESE REGULATIONS MAY BE COSTLY AND OUR FAILURE TO COMPLY COULD
LIMIT OUR ABILITY TO CONTINUE MARKETING AND DISTRIBUTING THESE PRODUCTS.

Even after drugs have been approved for sale, the FDA continues to
regulate their sale. These post-approval regulatory requirements may require
further testing and/or clinical studies, and may limit our ability to market and
distribute the product or may limit the use of the product. Under the Cellegy
License Agreement, we are responsible for all post-approval regulatory
compliance. If we fail to comply with the regulatory requirements of the FDA, we
may be subject to one or more of the following administrative or judicially
imposed sanctions:

o warning letters;

o civil penalties;

o criminal penalties;

o injunctions;

o product seizure or detention;

o product recalls;

o total or partial suspension of production; and

o FDA refusal to approve pending NDAs, or supplements to approved NDAs.

FDA APPROVAL DOES NOT GUARANTEE COMMERCIAL SUCCESS. IF WE FAIL TO SUCCESSFULLY
COMMERCIALIZE OUR PRODUCTS, OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF
OPERATIONS COULD BE MATERIALLY AND ADVERSELY AFFECTED.

Even if a product is approved for sale to the general public, its
commercial success will depend on our marketing efforts and acceptance by the
general public. The commercial success of any drug or medical or diagnostic
device depends on a number of factors, including:

o demonstration of clinical efficacy and safety;

o cost;

o reimbursement policies of large third-party payors;

o competitive products;

o convenience and ease of administration;

o potential advantages over alternative treatment methods;

o marketing and distribution support; and

o successfully creating and sustaining demand.

We cannot assure you that any of our future products will achieve
commercial success, regardless of how effective they may be.

CONSOLIDATION OF THE WHOLESALE DISTRIBUTION NETWORK FOR PHARMACEUTICAL PRODUCTS
COULD ADVERSELY IMPACT THE TERMS AND CONDITIONS OF OUR PRODUCT SALES.

The distribution network for pharmaceutical products has recently
experienced significant consolidation among wholesalers and chain stores. As a
result, a few large wholesale distributors control a significant share of the
market and we have less ability to negotiate price, return policies and other
terms and related provisions of the sale. If our distribution of products
expands, some of these wholesalers and distributors may account for a
significant portion of our product sales. Our inability to negotiate favorable
terms and conditions for product sales to those wholesalers could have a
material adverse effect on our business, financial condition and results of
operations.

FAILURE TO OBTAIN ADEQUATE REIMBURSEMENT COULD LIMIT OUR ABILITY TO MARKET
PRODUCTS.

Our ability to commercialize products, including licensed or acquired products,
will depend in part on the reimbursements, if any, obtained from third-party
payors such as government health administration authorities, private health
insurers, managed care programs and other organizations. Third-party payors are
increasingly attempting to contain healthcare costs by limiting both coverage
and the level of reimbursement for pharmaceutical products and medical devices.
Cost control initiatives could decrease the price that we would receive for
products and affect our ability to commercialize any product. Third-party payors
also tend to discourage use of branded products when generic substitutes are
available. As a result, reimbursement may not be available to enable us to
maintain price levels sufficient to realize an appropriate return on our
investment in product acquisition and development. If adequate reimbursement
levels for either newly approved or branded products are not provided, our
business, financial condition and results of operations could be materially and
adversely affected.

USE OF PROCEEDS

All proceeds from the sale of the common stock offered hereby will be
for the account of the selling stockholders. We will not receive any of the
proceeds from the sale from time to time of the common stock offered hereby. All
expenses of registration incurred in connection with this offering are being
borne by us, but all selling and other expenses incurred by any selling
stockholder will be borne by such selling stockholder.

SELLING STOCKHOLDERS

This prospectus covers possible sales by our officers, directors and
affiliates of shares they acquire through exercise of stock options, restricted
stock and other common stock-based awards granted under the Stock Plan.
Non-affiliates that are not named in this prospectus holding the lesser of 1,000
shares or one percent of the shares issuable under the Stock Plan may use this
prospectus to sell up to the lesser of 1,000 shares or one percent of the shares
issuable under the Stock Plan. Information regarding the selling stockholders,
including the number of shares offered for sale, will be set forth in a
prospectus supplement to the extent required. The address of the selling
stockholders is in care of PDI at Saddle River Executive Centre, 1 Route 17
South, Saddle River, New Jersey 07458.

PLAN OF DISTRIBUTION

We are registering the shares of common stock covered by this reoffer
prospectus for the account of the selling stockholders.

The selling stockholders may sell the shares in one or more
transactions (which may involve one or more block transactions) on the NASDAQ
National Market System, in sales occurring in the public market of such system,
in privately negotiated transactions or in a combination of such transactions.
Each such sale may be made either at market prices prevailing at the time of
such sale or at negotiated prices. The selling stockholders may sell some or all
of the shares in transactions involving broker-dealers, who may act as agent or
acquire the shares as principal. Any broker-dealer participating in such
transactions as agent may receive commissions from the selling stockholders
(and, if they act as agent for the purchaser of such shares, from such
purchaser). The selling stockholders will pay usual and customary brokerage
fees. Broker-dealers may agree with the selling stockholders to sell a specified
number of shares at a stipulated price per share and, to the extent such a
broker-dealer is unable to do

so acting as agent for the selling stockholders, to purchase as principals any
unsold shares at the price required to fulfill the respective broker-dealer's
commitment to the selling stockholders. Broker-dealers who acquire shares as
principals may thereafter resell such shares from time to time in transactions
(which may involve cross and block transactions and which may involve sales to
and through other broker-dealers, including transactions of the nature described
above) in the over-the-counter market, negotiated transactions or otherwise, at
market prices prevailing at the time of sale or at negotiated prices, and in
connection with such resales may pay to or receive from the purchasers of such
shares commissions.

To our knowledge, there is currently no agreement with any broker or
dealer respecting the sale of the shares offered hereby. Certain of our
executive officers participate in 10b5-1 plans that are administered by brokers
or dealers. Upon the sale of any such shares, the selling stockholders or anyone
effecting sales on behalf of the selling stockholders may be deemed an
underwriter, as that term is defined under the Securities Act of 1933, as
amended (the "Act").

We will pay all costs relating to the registration of the shares of
common stock and the preparation and reproduction of this reoffer prospectus.
However, any commissions or other fees payable to broker-dealers in connection
with any sale of the shares will be borne by the selling stockholders or other
party selling such shares. We will not receive any proceeds from the sale of
shares of common stock by the selling stockholders.

In order to comply with certain states' securities laws, if applicable,
the shares will be sold in such jurisdictions only through registered or
licensed brokers or dealers. In certain states the shares may not be sold unless
the shares have been registered or qualified for sale in such state, or unless
an exemption form registration or qualification is available and is obtained.

LEGAL MATTERS

Beth R. Jacobson, who is giving an opinion regarding the legality of
the securities registered hereby, is Executive Vice President, General Counsel
and Corporate Secretary of PDI, Inc. As of March 11, 2005, Ms. Jacobson owned
6,250 restricted shares of PDI's common stock and options to purchase 35,000
shares of PDI's common stock.

EXPERTS

The financial statements incorporated in this prospectus by reference
to the Annual Report on Form 10-K of PDI, Inc. for the year ended December 31,
2004, have been so incorporated in reliance on the report of
PricewaterhouseCoopers LLP, independent accountants.

AVAILABLE INFORMATION

PDI is subject to the informational requirements of the Exchange Act of
1934, as amended (the "Exchange Act"), and in accordance therewith files
reports, proxy and information statements and other information with the SEC.
Such reports, proxy and information statements and other information can be
inspected and copied at the Public Reference Room maintained by the SEC at 450
Fifth Street, N.W., Washington, D.C. 20549. You may obtain information on the
operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The
SEC maintains an Internet site at http://www.sec.gov that contains reports,
proxy and information statements and other information regarding issuers that
file electronically with the SEC, including PDI. PDI's common stock is listed
and traded on the NASDAQ National Market System.

DOCUMENTS INCORPORATED BY REFERENCE

The SEC allows "incorporation by reference" into this prospectus of
information that PDI files with the SEC. This permits PDI to disclose important
information to you by referencing these filed documents. Any information
referenced in this way is considered part of this prospectus, and any
information filed with the SEC

subsequent to the date of this prospectus will automatically be deemed to update
and supersede this information. PDI incorporates by reference the following
documents that have been filed with the SEC:

o Registration Statement on Form 8-A, dated May 13, 1998, relating to
registration of shares of PDI's common stock;

o Annual Report on Form 10-K for the year ended December 31, 2004; and

o Current Report on Form 8-K dated March 10, 2005.

PDI incorporates by reference the documents listed above and any future
filings made with the SEC in accordance with Sections 13(a), 13(c), 14 or 15(d)
of the Exchange Act prior to the filing of a post-effective amendment hereto
which indicates that all securities offered hereby have been sold or which
deregisters all securities then remaining unsold.

PDI will provide without charge to each person to whom a copy of this
prospectus has been delivered, upon the written or oral request of such person,
a copy of any or all of the documents referred to above which have been or may
be incorporated by reference herein (other than exhibits to such documents
unless such exhibits are specifically incorporated by reference in such
documents). Requests for such copies should be directed to Beth R. Jacobson,
Executive Vice President, General Counsel and Corporate Secretary, PDI, Inc.,
(telephone (201) 258-8450).

INDEMNIFICATION

PDI's Certificate of Incorporation provides for indemnification of its
directors, officers, employees, and agents against all expenses, liabilities and
losses, including attorneys' fees, judgments, fines, ERISA excise taxes (or
penalties and amounts paid or to be paid in settlement) reasonably incurred or
suffered by such person in connection therewith to the fullest extent authorized
by the Delaware General Corporation Law. In addition, Section 145 of the General
Corporation Law of the State of Delaware provides generally that a person sued
as a director, officer, employee or agent of a corporation may be indemnified by
the corporation for expenses, including counsel fees, judgments, fines and
amounts paid in settlement actually and reasonably incurred by such person in
connection with such action, suit or proceeding if in the case of other than
derivative suits, the person has acted in good faith and in a manner the person
reasonably believed to be in or not opposed to the best interests of the
corporation (and with respect to any criminal action or proceeding, had no
reasonable cause to believe that the person's conduct was unlawful). In the case
of a derivative suit, a director, officer, employee or agent of the corporation
who is not protected by the Certificate of Incorporation, may be indemnified by
the corporation for expenses, including counsel fees, actually and reasonably
incurred by the person in connection with defense or settlement of such action
or suit if such person has acted in good faith and in a manner the person
reasonably believed to be in or not opposed to the best interests of the
corporation, except that no indemnification shall be made in the case of a
derivative suit in respect of any claim as to which a director, officer,
employee or agent has been adjudged to be liable to the corporation unless the
Delaware Court of Chancery or the court in which such action or suit was brought
shall determine that such person is fairly and reasonably entitled to indemnity
for proper expenses. Indemnification is mandatory in the case of a present or
former director or officer who is successful on the merits in defense of a suit
against such person.

PDI also maintains directors' and officers' liability insurance. The
specific terms and provisions of the insurance policies limit such coverage.

Insofar as indemnification for liabilities arising under the Act may be
permitted to directors, officers and persons controlling PDI pursuant to the
foregoing provisions, or otherwise, PDI has been informed that in the opinion of
the SEC such indemnification is against public policy as expressed in the Act,
and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by PDI of expenses incurred or
paid by a director, officer or controlling person of PDI in the successful
defense of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered, PDI
will, unless in the opinion of its counsel the matter has been settled by
controlling precedent,

submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Act and will
be governed by the final adjudication of such issue.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents are incorporated by reference in this
registration statement:

(a) The Registrant's latest Annual Report on Form 10-K, filed
pursuant to Sections 13(a) or 15(d) of the Securities Exchange
Act of 1934 (the "Exchange Act").

(b) All other reports filed by the Registrant pursuant to Section
13(a) or 15(d) of the Exchange Act since the end of the fiscal
year covered by the annual report referred to in (a) above.

(c) The descriptions of the Common Stock that is contained in the
Registrant's registration statements filed under Section 12 of
the Exchange Act, including any amendment or report filed for
the purpose of updating such descriptions.

All documents subsequently filed by the Registrant pursuant to Sections
13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a
post-effective amendment which indicates that all securities offered hereby have
been sold or which deregisters all securities then remaining unsold, shall be
deemed to be incorporated by reference herein and to be a part hereof from the
date of filing of such documents.

Item 4. Description of Securities.

Not applicable.

Item 5. Interests of Named Experts and Counsel.

Beth R. Jacobson, who is giving an opinion regarding the legality of
the securities registered hereby, is Executive Vice President, General Counsel
and Corporate Secretary of the Registrant. As of March 11, 2005, Ms. Jacobson
owned 6,250 restricted shares of Common Stock and options to purchase 35,000
shares of Common Stock.

Item 6. Indemnification of Directors and Officers.

PDI also maintains directors' and officers' liability insurance. The
specific terms and provisions of the insurance policies limit such coverage.

Item 7. Exemption from Registration Claimed.

Not applicable.

Item 8. Exhibits.

The following exhibits are filed as part of this registration
statement.

Exhibit Number Description
- --------------------------------------------------------------------------------

4.1 The Certificate of Incorporation of the Registrant (Filed
as Exhibit 3.1 to the Registrant's Registration Statement
on Form S-1, Registration No. 333-46321, and incorporated
herein by reference).

4.2 Certificate of Amendment to the Certificate of
Incorporation of the Registrant (Filed as an exhibit to
the Registrant's Annual Report on Form 10-K for the year
ended December 31, 2001, and incorporated herein by
reference).

4.3 The Bylaws of the Registrant in effect on the date hereof
(Filed as an exhibit to the Registrant's Registration
Statement on Form S-1, Registration No. 333-46321, and
incorporated herein by reference).

4.4 2004 Stock Award and Incentive Plan (filed as an exhibit
to the Registrant's Proxy Statement for the Annual Meeting
of Shareholders held on June 16, 2004, and incorporated
herein by reference).

5.1 Opinion of Beth R. Jacobson, Esq. as to the legality of
the Common Stock offered hereby.

23.1 Consent of Beth R. Jacobson, Esq. (included as part of
Exhibit 5.1 hereto).

23.2 Consent of PricewaterhouseCoopers LLP.

Item 9. Undertakings.

(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales
are being made, a post-effective amendment to the
registration statement:

(i) To include any prospectus required by
Section 10(a)(3) of the Act;

(ii) To reflect in the prospectus any facts or
events arising after the effective date of
the registration statement (or the most
recent post-effective amendment thereof)
which, individually or in the aggregate,
represent a fundamental change in the
information set forth in the registration
statement; and

(iii) To include any material information with
respect to the plan of distribution not
previously disclosed in the registration
statement or any material change to such
information in the registration statement;

PROVIDED, HOWEVER, that paragraph (a)(1)(i) and (a)(1)(ii) do not apply if the
information required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed with or furnished to the
Commission by the Registrant pursuant to Sections 13 or 15(d) of the Exchange
Act that are incorporated by reference in the registration statement.

(2) That, for the purpose of determining any liability
under the Act, each such post-effective amendment
shall be deemed to be a new registration statement
relating to the securities offered therein, and the
offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a
post-effective amendment any of the securities being
registered which remain unsold at the termination of
the offering.

(b) The undersigned Registrant hereby undertakes that, for
purposes of determining any liability under the Act, each
filing of the Registrant's annual report pursuant to Sections
13(a) or 15(d) of the Exchange Act, (and, where applicable,
each filing of an employee benefit plan's annual report
pursuant to Section 15(d) of the Exchange Act) that is
incorporated by reference in the registration statement shall
be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona
fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the
Act may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the provisions described
in Item 6, or otherwise, the Registrant has been advised that
in the opinion of the SEC such indemnification is against
public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer
or controlling person of the Registrant in the successful
defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the
securities being registered, the Registrant will, unless in
the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it
is against public policy as expressed in the Act and will be
governed by the final adjudication of such issue.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the
Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-8 and has duly caused this registration
statement to be signed in its behalf by the undersigned, thereunto duly
authorized, in the City of Saddle River, State of New Jersey, on the 14th day of
March, 2005.

PDI, INC.

By: /s/ Charles T. Saldarini
-------------------------------------------------
Name: Charles T. Saldarini
Title: Vice Chairman and Chief Executive Officer

KNOWN ALL MEN BY THESE PRESENTS that each person whose signature to
this registration statement appears below hereby constitutes and appoints
Charles T. Saldarini and Bernard C. Boyle, or either of them, as such person's
true and lawful attorney-in-fact and agent, with full power of substitution and
resubstitution, for such person and in such person's name, place and stead, in
any and all capacities, to sign any and all amendments to the registration
statement, including post-effective amendments, and registration statements
filed pursuant to Rule 462 under the Securities Act of 1933, and to file the
same, with all exhibits thereto, and other documents in connection therewith,
with the SEC, and does hereby grant unto each said attorney-in-fact and agent
full power and authority to do and perform each and every act and thing
requisite and necessary to be done in and about the premises, as fully to all
intents and purposes as such person might or could do in person, hereby
ratifying and confirming all that each said attorney-in-fact and agent, or any
substitute therefor, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration
statement has been signed by the following persons in the capacities on March
14, 2005.

Signature Title
- --------- -----

/s/ John P. Dugan Chairman of the Board of Directors
- ------------------------------------
John P. Dugan

Vice Chairman of the Board of Directors
/s/ Charles T. Saldarini and Chief Executive Officer
- ------------------------------------
Charles T. Saldarini

Chief Financial Officer and Treasurer
/s/ Bernard C. Boyle (principal accounting and financial
- ------------------------------------ officer)
Bernard C. Boyle

/s/ John M. Pietruski Director
- ------------------------------------
John M. Pietruski

/s/ Jan Martens Vecsi Director
- ------------------------------------
Jan Martens Vecsi

/s/ Frank J. Ryan Director
- ------------------------------------
Frank J. Ryan

/s/ Larry Ellberger Director
- ------------------------------------
Larry Ellberger

/s/ Dr. Joseph T. Curti Director
- ------------------------------------
Dr. Joseph T. Curti

/s/ John C. Federspiel Director
- ------------------------------------
John C. Federspiel

/s/ Stephen J. Sullivan Director
- ------------------------------------
Stephen J. Sullivan